Frank Aquila, Ari Blaut and Davis Wang have been named “Dealmakers of the Year” by The American Lawyer for advising Amgen on its pending $28 billion acquisition of Horizon Therapeutics, the largest life sciences acquisition announced in 2022. Negotiating the complex, cross-border transaction required working at a breakneck pace to top an earlier unsolicited bid from Sanofi. This marks the third time that Frank, S&C’s Senior M&A Partner, has received this distinction, and the first time for Ari, Co-Head of S&C’s U.S. Credit & Leveraged Finance practice, and Davis, Co-Head of the Firm’s Tax practice.
This deal reflects S&C’s dominance in the healthcare sector. In 2022, the Firm advised on Abiomed’s $18 billion acquisition by Johnson & Johnson, Biohaven Pharmaceuticals’ $11.6 billion acquisition by Pfizer and Haleon's demerger from GSK, which created the world's biggest stand-alone consumer health company.
S&C lawyers have been named “Dealmakers of the Year” by The American Lawyer 26 times in the past 25 years, the most of any law firm.
Read our profile.
Subscribe to stay current on S&C Insights.
Sending an e-mail through this web site does not create an attorney-client relationship. You should not send us any information through this web site that you would want treated confidentially.